Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
N/A N=9 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
Phase 3 N=528 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hypertrophy
Primary: IPSS Change From Baseline — -5.6 Units on a scale — p=<0.001
N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
N/A N=45 Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
Phase 3 N=97 A Study in Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone — -0.01; 0.00 ratio — p=0.121
Phase 4 N=1,658 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
Prostatic Hyperplasia
Primary: Number of Men With Confirmed Diagnosis of BPH — 386; 437 Participants
Phase 3 N=511 A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks — -4.2; -6.3; -5.7 units on a scale — p=0.001
Phase 3 N=4,844 Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
Prostatic Hyperplasia
Primary: Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods. — 29; 27; 40; 14 events…
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
Phase 3 N=461 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
Benign Prostatic Hyperplasia (BPH)
Primary: International Prostate Symptom Score (IPSS) — 21.5; 21.4; -6.5; -3.6 Units on a 0 to 35 scale
Phase 3 N=462 A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
Benign Prostatic Hyperplasia
Primary: Measuring Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks — 21.2; 21.2; -6.3; -3.4 Units on a scale
Phase 3 N=1,058 Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis — 17.08; 17.30; -2.25; -4.92 units on a scale — p=<0.001
N/A N=10 MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
BPH · Prostate Hyperplasia · Urinary Frequency/Urgency
Primary: International Prostate Symptom Score (IPSS) Change — -17.5 units on a scale
N/A N=45 Study of Median Lobe Prostatic UroLift Procedure
Benign Prostatic Hyperplasia (BPH)
Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change
Phase 3 N=661 The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
Benign Prostatic Hyperplasia
Primary: Adverse Events — 431; 188; 29; 0 participants
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
N/A N=50 Rezum I Pilot Study for Benign Prostatic Hyperplasia
Prostatic Hyperplasia · Benign Prostatic Hyperplasia · Adenoma, Prostatic
Primary: International Prostate Symptom Score (IPSS) Change From Baseline — -0.4; -5.0; -13.1; -12.6 score on a scale
Phase 3 N=1,070 A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
Benign Prostatic Hyperplasia · Enlarged Prostate
Primary: Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks — -5.18; -3.76 units on a scale — p=0.001
Phase 2 N=315 Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
Phase 4 N=150 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
Benign Prostatic Hyperplasia
Primary: Percentage of Participants With Treatment Success — 84.9 percentage of participants
N/A N=248,393 Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
Prostatic Hyperplasia
Primary: Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis — 122307; 9456; 3293; 3674 participants
Phase 2 N=200 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax) — 54.83; 56.87; 1.92; -2.95 centimeters of water (cm H20) — p=0.068
N/A N=197 Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptom
Primary: Efficacy: Change From Baseline in the International Prostate Symptom Score (IPSS) at 3 Month Follow-Up — -11.2; -4.3 Cange in IPSS score
Phase 3 N=325 Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) — -5.6; -3.6 Units on a Scale — p=0.004
Phase 2 N=134 Botulinum Toxin Injection for the Management of BPH
Benign Prostatic Hyperplasia
Primary: Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. — 46; 50 participants — p=<0.05
N/A N=41 Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: International Prostate Symptom Score (IPSS) — 9.83; 13.6; -3.39; -5.94 units on a scale
N/A N=101 Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Benign Prostatic Hyperplasia (BPH)
Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage